Post-approval studies (Phase 4)Study completedNCT03440736
What this trial is testing
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
Who this might be right for
PsoriasisMetabolic Syndrome
Novartis Pharmaceuticals 781